FOFrancis Anthony O'Neill

Francis Anthony O'Neill

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Francis Anthony O'Neill has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Dynamic changes of functional segregation and integration in vulnerability and resilience to schizophrenia

    by Jia Duan, Mingrui Xia, Fay Y. Womer, Miao Chang, Zhiyang Yin, Qian Zhou, Yue Zhu, Zhuang Liu, Xiaowei Jiang, Shengnan Wei, et al.

    Schizophrenia (SZ) is a highly heritable disease with neurodevelopmental origins and significant functional brain network dysfunction. Functional network is heavily influenced by neurodevelopment processes and can be characterized by the degree of segregation and integration. This study examines functional segregation and integration in SZ and their first‐degree relatives (high risk [HR]) to better understand the dynamic changes in vulnerability and resiliency, and disease markers. Resting‐state functional magnetic resonance imaging data acquired from 137 SZ, 89 HR, and 210 healthy controls (HCs). Small‐worldness σ was computed at voxel level to quantify balance between segregation and integration. Interregional functional associations were examined based on Euclidean distance between regions and reflect degree of segregation and integration. Distance strength maps were used to localize regions of altered distance‐based functional connectivity. σ was significantly decreased in SZ compared to HC, with no differences in high risk (HR). In three‐group comparison, significant differences were noted in short‐range connectivity (primarily in the primary sensory, motor and their association cortices, and the thalamus) and medium/long‐range connectivity (in the prefrontal cortices [PFCs]). Decreased short‐ and increased medium/long‐range connectivity was found in SZ. Decreased short‐range connectivity was seen in SZ and HR, while HR had decreased medium/long‐range connectivity. We observed disrupted balance between segregation and integration in SZ, whereas relatively preserved in HR. Similarities and differences between SZ and HR, specific changes of SZ were found. These might reflect dynamic changes of segregation in primary cortices and integration in PFCs in vulnerability and resilience, and disease markers in SZ.


  • Open Access

    Age at first birth in women is genetically associated with increased risk of schizophrenia

    by Guiyan Ni, Jacob Gratten, Naomi R. Wray, Sang Hong Lee, Stephan Ripke, Benjamin M. Neale, Aiden Corvin, James T. R. Walters, Kai-How Farh, Peter A. Holmans, et al.

    Previous studies have shown an increased risk for mental health problems in children born to both younger and older parents compared to children of average-aged parents. We previously used a novel design to reveal a latent mechanism of genetic association between schizophrenia and age at first birth in women (AFB). Here, we use independent data from the UK Biobank (N = 38,892) to replicate the finding of an association between predicted genetic risk of schizophrenia and AFB in women, and to estimate the genetic correlation between schizophrenia and AFB in women stratified into younger and older groups. We find evidence for an association between predicted genetic risk of schizophrenia and AFB in women (P-value = 1.12E-05), and we show genetic heterogeneity between younger and older AFB groups (P-value = 3.45E-03). The genetic correlation between schizophrenia and AFB in the younger AFB group is −0.16 (SE = 0.04) while that between schizophrenia and AFB in the older AFB group is 0.14 (SE = 0.08). Our results suggest that early, and perhaps also late, age at first birth in women is associated with increased genetic risk for schizophrenia in the UK Biobank sample. These findings contribute new insights into factors contributing to the complex bio-social risk architecture underpinning the association between parental age and offspring mental health.


  • Open Access

    Enhancing Psychosis-Spectrum Nosology Through an International Data Sharing Initiative

    by Anna R Docherty, Eduardo Fonseca-Pedrero, Martin Debbané, Raymond C K Chan, Richard J Linscott, Katherine G Jonas, David C Cicero, Melissa J Green, Leonard J Simms, Oliver Mason, et al.

    The latent structure of schizotypy and psychosis-spectrum symptoms remains poorly understood. Furthermore, molecular genetic substrates are poorly defined, largely due to the substantial resources required to collect rich phenotypic data across diverse populations. Sample sizes of phenotypic studies are often insufficient for advanced structural equation modeling approaches. In the last 50 years, efforts in both psychiatry and psychological science have moved toward (1) a dimensional model of psychopathology (eg, the current Hierarchical Taxonomy of Psychopathology [HiTOP] initiative), (2) an integration of methods and measures across traits and units of analysis (eg, the RDoC initiative), and (3) powerful, impactful study designs maximizing sample size to detect subtle genomic variation relating to complex traits (the Psychiatric Genomics Consortium [PGC]). These movements are important to the future study of the psychosis spectrum, and to resolving heterogeneity with respect to instrument and population. The International Consortium of Schizotypy Research is composed of over 40 laboratories in 12 countries, and to date, members have compiled a body of schizotypy- and psychosis-related phenotype data from more than 30000 individuals. It has become apparent that compiling data into a protected, relational database and crowdsourcing analytic and data science expertise will result in significant enhancement of current research on the structure and biological substrates of the psychosis spectrum. The authors present a data-sharing infrastructure similar to that of the PGC, and a resource-sharing infrastructure similar to that of HiTOP. This report details the rationale and benefits of the phenotypic data collective and presents an open invitation for participation.


  • Occurrence and co-occurrence of hallucinations by modality in schizophrenia-spectrum disorders

    by Simon McCarthy-Jones, David Smailes, Aiden Corvin, Michael Gill, Derek W. Morris, Timothy G. Dinan, Kieran C. Murphy, F. Anthony O′Neill, John L. Waddington, Australian Schizophrenia Research Bank, et al.


  • Open Access

    Proof of concept: Molecular prediction of schizophrenia risk

    by Anna R. Docherty, Arden Moscati, Daniel E. Adkins, Gemma T. Wallace, Guarav Kumar, Brien P. Riley, Aiden Corvin, F. Anthony O’neill, Michael Gill, Kenneth S. Kendler, et al.

    Key Points: Question: To what extent do global polygenic risk scores (PRS), molecular pathway-specific PRS, complement component (C4) gene expression, MHC loci, sex, and ancestry jointly contribute to risk for schizophrenia-spectrum disorders (SZ)? Findings: Global polygenic risk for schizophrenia, sex, and their interaction most robustly predict risk in a classification and regression tree model, with highest risk groups having 50/50 chance of SZ. Meaning: Psychometric risk indicators, such as prodromal symptom assessments, may be enhanced by the examination of genetic risk metrics. Preliminary results suggest that of genetic risk metrics, global polygenic information has the most potential to significantly aide in the prediction of SZ. Importance: Schizophrenia (SZ) has a complex, heterogeneous symptom presentation with limited established associations between biological markers and illness onset. Many (gene) molecular pathways (MPs) are enriched for SZ signal, but it is still unclear how these MPs, global PRS, major histocompatibility complex (MHC) complement component (C4) gene expression, and MHC loci might jointly contribute to SZ and its clinical presentation. It is also unclear whether sex or ancestry interacts with these metrics to increase risk in certain individuals. Objective: To examine multiple genetic metrics, sex, and their interactions as possible predictors of SZ risk. Genetic information could aid in the clinical prediction of risk, but it is still unclear which genetic metrics are most promising, and how sex interacts with genetic risk metrics. Design, Setting, and Participants: To examine molecular risk in a proof-of-concept study, we used the Wellcome Trust case-control cohort and classified cases as a function of 1) polygenic risk score (PRS) for both whole genome and for 345 implicated molecular pathways, 2) predicted C4 expression, 3) SZ-relevant MHC loci, 4) sex, and 5) ancestry. Main Outcomes and Measures: PRSs, C4 expression, SZ-relevant MHC loci, sex, and ancestry as joint risk factors for SZ. Results: Recursive partitioning yielded 15 molecular risk classes and retained as significant psychosis classifiers only sex, genome-wide SZ polygenic risk, and one MP PRS. Sex was the most robust classifier in a stepwise regression, and there was a significant interaction of sex with SZ PRS on case status, suggesting males have a lower polygenic risk threshold. By down-sampling case proportion to 1% and 1.4% population base rates in males and females, respectively, high-risk subtypes defined by this model had roughly a 52% odds of developing SZ (individuals with SZ PRS elevated by 2.6 SDs; incidence = 51.8%). Conclusions and Relevance: This proof-of-concept suggests that global SZ PRS, sex, and their interaction are robust predictors of risk and that males have a lower PRS threshold for onset. Implications for the integration of these metrics with psychometrically-identified risk are discussed.


  • Top Cited Papers
    Open Access

    Contribution of copy number variants to schizophrenia from a genome-wide study of 41,321 subjects

    by Christian R Marshall, Psychosis Endophenotypes International Consortium, Daniel P Howrigan, Daniele Merico, Bhooma Thiruvahindrapuram, Wenting Wu, Douglas S Greer, Danny Antaki, Aniket Shetty, Peter A Holmans, et al.

    The CNV analysis group of the Psychiatric Genomic Consortium analyzes a large schizophrenia cohort to examine genomic copy number variants (CNVs) and disease risk. They find an enrichment of CNV burden in cases versus controls and identify 8 genome-wide significant loci as well as novel suggestive loci conferring either risk or protection to schizophrenia. Copy number variants (CNVs) have been strongly implicated in the genetic etiology of schizophrenia (SCZ). However, genome-wide investigation of the contribution of CNV to risk has been hampered by limited sample sizes. We sought to address this obstacle by applying a centralized analysis pipeline to a SCZ cohort of 21,094 cases and 20,227 controls. A global enrichment of CNV burden was observed in cases (odds ratio (OR) = 1.11, P = 5.7 × 10−15), which persisted after excluding loci implicated in previous studies (OR = 1.07, P = 1.7 × 10−6). CNV burden was enriched for genes associated with synaptic function (OR = 1.68, P = 2.8 × 10−11) and neurobehavioral phenotypes in mouse (OR = 1.18, P = 7.3 × 10−5). Genome-wide significant evidence was obtained for eight loci, including 1q21.1, 2p16.3 (NRXN1), 3q29, 7q11.2, 15q13.3, distal 16p11.2, proximal 16p11.2 and 22q11.2. Suggestive support was found for eight additional candidate susceptibility and protective loci, which consisted predominantly of CNVs mediated by nonallelic homologous recombination.


  • Open Access

    The Influence of Genotype Information on Psychiatrists’ Treatment Recommendations: More Experienced Clinicians Know Better What to Ignore

    by Alan J. McMichael, Marco Boeri, Jonathan J. Rolison, Joe Kane, Francis A. O’neill, Ric Scarpa, Frank Kee


  • Top Cited Papers

    Modeling Linkage Disequilibrium Increases Accuracy of Polygenic Risk Scores

    by Bjarni J. Vilhjálmsson, Jian Yang, Hilary K. Finucane, Alexander Gusev, Sara Lindström, Stephan Ripke, Giulio Genovese, Po-Ru Loh, Gaurav Bhatia, Ron Do, et al.


  • Open Access

    Meta-analysis of Positive and Negative Symptoms Reveals Schizophrenia Modifier Genes: Table 1.

    by Alexis C. Edwards, Tim B. Bigdeli, Anna R. Docherty, Silviu Bacanu, Donghyung Lee, Teresa R. de Candia, Arden Moscati, Dawn L. Thiselton, Brion S. Maher, Brandon K. Wormley, et al.

    Background: Evidence suggests that genetic factors may influence both schizophrenia (Scz) and its clinical presentation. In recent years, genome-wide association studies (GWAS) have demonstrated considerable success in identifying risk loci. Detection of “modifier loci” has the potential to further elucidate underlying disease processes. Methods: We performed GWAS of empirically derived positive and negative symptom scales in Irish cases from multiply affected pedigrees and a larger, independent case–control sample, subsequently combining these into a large Irish meta-analysis. In addition to single-SNP associations, we considered gene-based and pathway analyses to better capture convergent genetic effects, and to facilitate biological interpretation of these findings. Replication and testing of aggregate genetic effects was conducted using an independent European-American sample. Results: Though no single marker met the genome-wide significance threshold, genes and ontologies/pathways were significantly associated with negative and positive symptoms; notably, NKAIN2 and NRG1 , respectively. We observed limited overlap in ontologies/pathways associated with different symptom profiles, with immune-related categories over-represented for negative symptoms, and addiction-related categories for positive symptoms. Replication analyses suggested that genes associated with clinical presentation are generalizable to non-Irish samples. Conclusions: These findings strongly support the hypothesis that modifier loci contribute to the etiology of distinct Scz symptom profiles. The finding that previously implicated “risk loci” actually influence particular symptom dimensions has the potential to better delineate the roles of these genes in Scz etiology. Furthermore, the over-representation of distinct gene ontologies/pathways across symptom profiles suggests that the clinical heterogeneity of Scz is due in part to complex and diverse genetic factors.


  • Genome-wide gene pathway analysis of psychotic illness symptom dimensions based on a new schizophrenia-specific model of the OPCRIT

    by Anna R. Docherty, T. Bernard Bigdeli, Alexis C. Edwards, Silviu Bacanu, Donghyung Lee, Michael C. Neale, Brandon K. Wormley, Dermot Walsh, F. Anthony O'NEill, Brien P. Riley, et al.